MMV Board of Directors

Prof. Peter G Smith  Professor of Tropical Epidemiology, LSHTM, UK  
Dr Christopher J Elias  President, Program for Appropriate Technology in Health, WA, USA  
Dr Robert D Newman  Director of the Global Malaria Programme, WHO, Switzerland on behalf of Dr Hiroki Nakatani, Assistant Director-General – HIV/AIDS, TB, Malaria and Neglected Tropical Diseases, WHO, Switzerland  
Mr James Cochrane  Vice Chair TNT nv and Former Director, GlaxoWellcome plc, UK  
Dr Awa Marie Coll-Seck  Executive Director of the Roll Back Malaria Partnership; and Chairperson of MMV ADAC

Dr Dennis Schmatz  former Vice President, Head of Tsukuba Research Institute, Merck-Banyu Research Laboratories, Japan; Co-Chairperson of MMV ESAC  
Dr Winston E Gutteridge  Former Chief, Product R&D, TDR, WHO, Switzerland; and Chairman of MMV ESAC 2003-2009.  
Mr Per Wold-Olsen  former President of Human Health Intercontinental Region, Merck & Co., Inc., former Member of Merck’s Management Committee  
Lynda, Baroness Chalker of Wallasey  Chairman, Africa Matters Ltd, UK; and Chairman of MMV Board since 2006  
Dr Chris Hentschel  President and Chief Executive Officer, MMV, Switzerland  
Dr Carlos M Morel  Director, Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (FIOCRUZ), Brazil; and former Director, TDR, WHO, Switzerland  

Dr Regina Rabinovich  Director, Infectious Diseases, Global Health Program, Bill and Melinda Gates Foundation, WA, USA  
Dr Pedro Alonso  Director, Barcelona Centre for International Health Research (CRESIB), Hospital Clinic, University of Barcelona, Spain  

Not pictured:  
Dr Ernest Darkoh  Chairman & Founding Partner, BroadReach Healthcare, South Africa  
Dr Pascoal M Mocumbi  High Representative of the European and Developing Countries Clinical Trials Partnership; and former Prime Minister of Mozambique

MMV North America Inc.

Dr J Carl Craft  former Chief Scientific Officer, MMV, Switzerland  
Dr Christopher J Elias  Chairman of MMV North America Inc. (see above)

Dr Dennis Schmatz (see above)  
Mr Jim Geraghty  Senior Vice-President, Genzyme Corporation, MA, USA  
Dr Chris Hentschel (see above)  
Ms Wendy Taylor  Senior Vice-President, Global Advocacy, Malaria No More, NY, USA
Global Safety Board

Sir Colin Dollery  Senior Consultant, Glaxo-SmithKline Research and Development, UK
Dr Stephan Duparc  Medical Director, MMV, Switzerland; and Co-Chairman of MMV Global Safety Board
Dr Neil Garbett  Independent Consultant Pharmaceutical Physicist and Consulting Partner to Kinhapte Ltd, UK
Dr Trevor Gibbs  Senior Vice President, Pharmacovigilance & Medical Governance, GlaxoSmithKline, UK; and Co-Chairman of MMV Global Safety Board

Dr Maurizio Maniani  General Manager, RBM S.P.A. and Global Head of Exploratory/Translational Medicine, Merck Serono Research, Italy
Dr David McGibney  Pharmaceutical research and development expert; Consultant Pharmaceutical Physician
Prof. Munir Piromhamed  Professor of Clinical Pharmacology, University of Liverpool, UK

Access and Delivery Advisory Committee (ADAC)

Mr Joseph Amoussou  Retail Pharmacist, Benin
Mr Girindra Beeharry  Sr. Program Officer, Policy & Finance Global Health, Bill and Melinda Gates Foundation, WA, USA
Prof. Awa Marie Coll-Seck  Executive Director of the Roll Back Malaria Partnership, Switzerland; and Chairperson of MMV ADAC
Dr Issa Diop  Technical Advisor to the Minister of Health, Senegal
Mr Paul Lalvani  CEO, O3i, India
Mr P A Narayan  Vice President, Strides Arcolab Ltd, India
Dr Naawa Sipilanyambe  Health Specialist (Malaria Scale-up), UNICEF, NY, USA
Dr Francisco Songane  Former Minister of Health, Mozambique
Prof. Marcel Tanner  Director, Swiss Tropical and Public Health Institute, Switzerland
Prof. Geoff Targett  Deputy Director, Gates Malaria Partnership, LSHTM, UK
Prof. Prashant Yadav  Professor of Supply Chain Management, MIT-Zaragoza International Logistics Programme, Spain
Dr Hashim Yusufu  Deputy Director, National Agency for Food and Drug Administration and Control (NAFDAC), Nigeria
Behind the scenes

Chris Hentschel  President and Chief Executive Officer
Nada Araeipour  Legal Assistant
Jaya Banerji  Head, Communications
Ian Bathurst  Director, Drug Discovery and Technology
Isabelle Borghini-Fuhrer  Associate Director, Clinical Sciences
Jeremy Burrows  Associate Director, Drug Discovery
Renia Coglan  Associate Director, Global Access
Diana Cotran  Executive Vice President, Operations
Maud Couturier  Science Coordinator
Christine Crettenand  Assistant Manager, Finance and Budget
Matthew Doherty  Finance Assistant
Stephan Duparc  Medical Director
Julia Engelking  Associate Director, Corporate Development
Alejandro Estrada  Office Attendant
Pascal Fantauzzi  Associate Director, Drug Discovery
Sylvie Fonteilles-Drabek  Senior Legal Officer
Penny Grewal  Director, Global Access
Roberto Hanania  Contracts Officer
Joan Herbert  Business Development Manager
Andrew Humberstone  Associate Director, Translational Medicine
George Jago  Executive Vice President, Global Access
Franziska Karyabwite  Human Resources Administrator
Elizabeth Kernen  Administrative Assistant
Erin Kimaoui  Personal Assistant to the President and CEO/Website Administrator
Catherine Legier  Science Coordinator
Didier Leroy  Associate Director, Drug Discovery
Julie Lotharius  Associate Director, Translational Medicine
Maud Lugand  Global Access Project Coordinator
Jörg Möhrle  Director, Clinical Development
Patrick Nef  Executive Vice-President, Business Development
Claude Oeuvray  Associate Director, Portfolio Management
Sophie Pereira  Finance Assistant
Carla Pinoargote-Meister  Human Resources Generalist
Elizabeth Poll  Editor and Publications Officer
Peter Potter-Lesage  Chief Financial Officer
Elena Ramos  Personal Assistant to the Chief Scientific Officer
Samuel Sierro  Finance Officer
Yuko Takase  Finance Assistant
Ambrose Talisuna  Country Representative in Kampala
David Ubben  Director, Clinical Development
David Waterson  Associate Director, Drug Discovery
Timothy Wells  Chief Scientific Officer
MMV’s global network

AFRICA

Benin Centre de Recherche Entomologique de Cotonou
Botswana Botswana Institute for Research on Dis-Tropical Diseases, Gaborone
Cameroon Genetic Research and Training Centre, Douala
Cape Verde Centre of Medical Research, Mindelo
Central African Republic Institut Pasteur, Bangui
Chad Université de N'Djamena, N'Djamena
Comoros Centre de Recherche vétérinaire, Moroni
Congo Centre National de Recherche et de Formation sur le Paludisme, Kinshasa
Côte d’Ivoire Institut Pasteur, Abidjan
Democratic Republic of the Congo National Centre of Malaria Research and Control, Kinshasa
Equatorial Guinea Instituto Nacional de Salud, Malabo
Ethiopia National Institute of Health, Addis Ababa
Gabon Ministère de la Santé, Libreville
Ghana Kintampo Health Research Centre, Kintampo
Guinea Institut Pasteur de Guinée, Conacry
Kenya Kenya Medical Research Institute, Nairobi
Lesotho King’s Health Research Centre, Maseru
Madagascar Institut Pasteur, Antananarivo
Malawi Malawi College of Medicine, Lilongwe
Mali Institut National de Recherche et de Formation sur le Paludisme, Bamako
Mauritania Centre National de Recherche sur le Paludisme, Nouakchott
Mozambique National Institute of Tropical Medicine, Maputo
Namibia National Institute of Health, Windhoek
Niger National Institute of Malaria Control, Niamey
Nigeria National Institute of Tropical Disease Research, Enugu
Rwanda Institut National de Recherche en Santé, Kigali
Senegal Centre Suisse de Recherche Vétérinaire, Dakar
South Africa National Institute for Communicable Diseases, Johannesburg
Sudan National Institute of Malaria, Khartoum
Togo Institut Pasteur du Togo, Lomé
Uganda National Institute of Public Health, Kampala
Zambia Public Health Research Institute, Lusaka
Zimbabwe National Institute of Medical Research, Harare

AMERICA

Argentina Fundación Instituto Leloir, Buenos Aires
Bolivia Centro de Investigación en Salud Pública, La Paz
Brazil Fundação Oswaldo Cruz, Rio de Janeiro
Canada Canadian Blood Services, Ottawa
Chile Instituto de Salud Pública de Chile, Santiago
Colombia Fundación para la Investigación, Bogotá
Costa Rica Instituto de Salud Pública, San José
Cuba Instituto Nacional de Salud, Havana
Dominican Republic National Institute of Communicable Diseases, Santo Domingo
Ecuador Instituto Nacional de Salud, Quito
El Salvador Instituto de Salud, San Salvador
France Institut Pasteur, Paris
Guyana National Public Health Institute, Georgetown
Honduras CIRPAS, Tegucigalpa
Mexico Instituto Nacional de Salud Pública, Mexico City
Nicaragua National Institute of Health, Managua
Panama Instituto Nacional de Sanidad, Panama City
Paraguay Centro de Investigación en Salud Pública, Asunción
Peru Instituto de Salud, Lima
Puerto Rico Universidad de Puerto Rico, San Juan
Trinidad and Tobago Ministry of Health, Port of Spain
Uruguay Instituto Nacional de Salud, Montevideo

ASIA

Bangladesh National Institute of Health, Dhaka
Brunei National Institute of Public Health, Bandar Seri Begawan
Cambodia National Institute of Health, Phnom Penh
China Academy of Military Medical Sciences, Beijing
Cuba Instituto de Salud Pública, Havana
India National Institute of Malaria, New Delhi
Indonesia Kepala Badan Pengembangan Keahlian dan Modal Kerja, Jakarta
Iran Pasteur Institute of Iran, Tehran
Iranian Red Crescent, Tehran
Israel Sheba Medical Center, Tel Aviv
Jordan Centre for Disease Control and Prevention, Amman
Kazakhstan National Institute of Medicine, Almaty
Korea National Institute of Health, Seoul
Kyrgyz Republic National Institute of Health, Bishkek
Laos Ministry of Health, Vientiane
Malaysia Ministry of Health, Kuala Lumpur
Mongolia National Center of Public Health, Ulaanbaatar
Myanmar Public Health Department, Naypyidaw
Nepal National Research Centre on Malaria, Kathmandu
Philippines National Institute of Health, Manila
Singapore National University of Singapore, Singapore
South Korea National Institute of Health, Seoul
Thailand Ministry of Public Health, Bangkok
United Arab Emirates Ministry of Health and Prevention, Dubai
Vietnam National Institute of Hygiene and Epidemiology, Hanoi

Africans

Australia Australian National University, Canberra
Bangladesh National Institute of Public Health, Dhaka
Brazil Instituto de Infectologia, Rio de Janeiro
Bulgaria National Center for Infectious and Parasitic Diseases, Sofia
Canada Centre de Santé et de Services Sociaux, Montréal
China National Institute of Malaria, Beijing
Colombia Ministry of Health, Bogotá
India Public Health Research Institute, Mumbai
Indonesia National Institute of Health, Jakarta
Iran Ministry of Health, Tehran
Malaysia Ministry of Health, Kuala Lumpur
Mexico National Institute of Health, Mexico City
Myanmar Ministry of Health, Naypyidaw
Philippines National Institute of Health, Manila
Singapore National University of Singapore, Singapore
South Korea National Institute of Health, Seoul
Thailand Ministry of Health, Bangkok
United Arab Emirates Ministry of Health and Prevention, Dubai
Vietnam National Institute of Hygiene and Epidemiology, Hanoi

Europe

Austria Medical University of Vienna, Vienna
Belgium Institute of Tropical Medicine, Antwerp
Bulgaria National Center for Infectious and Parasitic Diseases, Sofia
Canada Public Health Agency, Ottawa
Chile Ministра de Salud, Santiago
China China National Institute of Parasitology and Vector Diseases, Beijing
Czech Republic National Institute of Public Health, Prague
Denmark National Institute of Public Health, Copenhagen
Estonia Institute of Entomology and Zoolo
Finland National Public Health Institute, Helsinki
France Institut Pasteur, Paris
Germany Robert Koch Institute, Berlin
Greece National Public Health Organisation, Athens
Hungary National Institute of Public Health, Budapest
Iceland National University Hospital, Reykjavik
India National Institute of Malaria, New Delhi
Ireland Health Service Executive, Dublin
Ireland National Institute for Health and Disability, Dublin
Israel Ministry of Health, Jerusalem
Italy National Institute of Health, Rome
Japan Japan Agency for International Cooperation, Tokyo
Korea Ministry of Health and Welfare, Seoul
Latvia Latvian National Research and Development Centre, Riga
Lithuania Public Health Centre, Vilnius
Luxembourg National Public Health Service, Luxembourg
Malaysia Ministry of Health, Kuala Lumpur
Morocco National Institute of Public Health, Rabat
Netherlands National Institute for Public Health and the Environment, Bilthoven
New Zealand Ministry of Health, Wellington
Norway National Institute of Public Health, Oslo
Poland National Institute of Public Health, Warsaw
Portugal National Institute for Health and Social Services, Lisbon
Romania National Institute of Public Health, Bucharest
Russia National Research Center for Tropical Medicine, Moscow
Scotland National Veterinary Services, Edinburgh
South Africa National Institute for Communicable Diseases, Johannesburg
Spain National Institute of Health, Madrid
Switzerland Federal Office of Public Health, Bern
Sweden National Institute of Public Health, Stockholm
United Kingdom Public Health England, London
United States Centers for Disease Control and Prevention, Atlanta

This list includes all the institutions, organizations and companies whom we are currently collaborating with in our science and access work, in addition to those with whom we have conducted clinical trials.
Why malaria needs you

- Malaria kills a child under 5 every 40 seconds.
- Of the million malaria deaths, 90% occur in Africa.
- Malaria is both a cause and a consequence of poverty.

Why malaria needs you now

- The threat of resistance to the most effective cures, Artemisinin-based Combination Therapies (ACTs), is real. We are discovering and developing new antimalarial drugs to tackle resistance.
- The most vulnerable populations continue to have limited access to effective antimalarials. We are working to change this.
- Eradicating malaria calls for an integrated approach focusing on more effective medicines, rapid diagnostic tests, insecticide-treated bed nets, indoor residual spraying and future vaccines. Medicines are the tip of the spear.

Why invest in MMV

MMV is the leading player in malaria drug research and development.

- MMV is a successful public-private partnership:
  - We supported the development and final launch, in 2009, of Coartem® Dispersible, the first affordable, high quality paediatric ACT for use in Africa.
  - We plan to launch two more new products by 2011.
- MMV’s innovative antimalarial pipeline contains over 50 cutting-edge projects and targets the eradication of malaria.
- MMV leverages public and private financial resources, world-class expertise and facilities, with over 130 partners globally.

Can we succeed?

With your funding, we can!
More new drugs are essential if we are to defeat malaria. MMV is researching the next generation of antimalarials that will help eradicate this disease.

Invest in MMV.
Help save lives.
Build a future without malaria.

For investment opportunities contact Julia Engelking at engelking@mmv.org and +41 79789 3427
Medicines for Malaria Venture has received financial support from the following organizations:

![Bill & Melinda Gates Foundation](image1)
![CRIMALDI](image2)
![ExxonMobil](image3)
![Irish Aid](image4)
![National Institutes of Health (NIH/NIAID)](image5)
![The Rockefeller Foundation](image6)
![Swiss Federal Office for the Protection of Agriculture and Food Safety](image7)
![UK aid](image8)
![Wellcome Trust](image9)
![The World Bank](image10)

MMV is also very grateful for the support it has received from a number of private individuals.

**Editors**
- Elizabeth Poll & Jaya Banerji, MMV

**Copy Editor**
- Melitta Campbell

**Designer**
- ComStone - Pierre Chassany, Geneva, Switzerland

**Lithograph and Printer**
- Genoud SA, Lausanne, Switzerland

**Photographs**
- Anna Wang (p20), Ben Moldenhauer (cover; pages 2, 4, 6, 8, 10, 12, 17, 22, 35, 42 & 59), BioFocus DPI AG (pages 33: 2), BPRC (p38), GNF (p41), Griffith University (p18), Imperial College (p39), MMV (pages 3, 7, 15, 45, 60 & 64), Monash University (p29), Pierre Chassany (p11), RBM (p9), Keystone/SPL/LSHTM (p24), Shing Poong Pharmaceuticals (p27) and University of South Florida (pages 33: 1 & 3)

© April 2010 Medicines for Malaria Venture

All rights are reserved by Medicines for Malaria Venture. The document may be freely reviewed and abstracted, with a clear and appropriate acknowledgment of source, but is not for sale or for use in conjunction with commercial purposes. Requests for permission to reproduce or translate the document, in part or in full, should be addressed to the administration of Medicines for Malaria Venture, where information on any translation or reprints is centralized.
Defeating malaria together

International Centre Cointrin
Route de Pré-Bois 20  PO Box 1826
1215 Geneva 15  Switzerland

Tel. +41 22 799 4060
Fax +41 22 799 4061
info@mmv.org
www.mmv.org